Cited by 93Diabetes Management and ResearchDiabetes, Cardiovascular Risks, and LipoproteinsPhysical Activity and Health

Use of Continuous Glucose Monitors by People Without Diabetes: An Idea Whose Time Has Come?

Open access
Klonoff, David C., Nguyen, Kevin T., Xu, Nicole Y., Gutierrez, Alberto, Espinoza, Juan C., Vidmar, Alaina P.·2023·Journal of Diabetes Science and Technology

Abstract

Background: Continuous glucose monitor (CGM) systems were originally intended only for people with diabetes. Recently, there has been interest in monitoring glucose concentrations in a variety of other situations. As data accumulate to support the use of CGM systems in additional states unrelated to diabetes, the use of CGM systems is likely to increase accordingly. Methods: PubMed and Google Scholar were searched for articles about the use of CGM in individuals without diabetes. Relevant articles that included sufficient details were queried to identify what cohorts of individuals were adopting CGM use and to define trends of use. Results: Four clinical user cases were identified: (1) metabolic diseases related to diabetes with a primary dysregulation of the insulin-glucose axis, (2) metabolic diseases without a primary pathophysiologic derangement of the insulin-glucose axis, (3) health and wellness, and (4) elite athletics. Seven trends in the use of CGM systems in people without diabetes were idenfitied which pertained to both FDA-cleared medical grade products as well as anticipated future products, which may be regulated differently based on intended populations and indications for use. Conclusions: Wearing a CGM has been used not only for diabetes, but with a goal of improving glucose patterns to avoid diabetes, improving mental or physical performance, and promoting motivate healthy behavioral changes. We expect that clinicians will become increasingly aware of (1) glycemic patterns from CGM tracings that predict an increased risk of diabetes, (2) specific metabolic glucotypes from CGM tracings that predict an increased risk of diabetes, and (3) new genetic and genomic biomarkers in the future.

Integrity signals

Registry

Crossref · 10.1177/19322968221110830

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Continuous use of CGMs in non-insulin users can be burdensome physically and financially and may not provide immediate perceived benefits.

    “continuous use of CGMs in non-insulin users can sometimes be burdensome both physically and financially due to the invasiveness and cost of the devices, and may not provide immediate perceived benefits7.”
  • Recent developments have made CGM more available to individuals with diet-controlled diabetes or no diabetes, placing CGM center-stage in efforts to prevent diabetes through lifestyle modifications.

    “recent developments have made CGM more available to individuals with diet-controlled diabetes or no diabetes, thereby placing CGM center-stage in efforts to prevent diabetes through lifestyle modifications such as healthier food choices and increased physical activity6,7.”

The citation lists haven’t been fetched yet

References 70 · Cited by 93

Authors
Klonoff, D. C., Nguyen, K. T., Xu, N. Y., Gutierrez, A., Espinoza, J. C., & Vidmar, A. P.
Affiliations
  • San Mateo Medical Center (US)
  • Diabetes Technology Society (US)
  • NDA Partners LLC, Bethesda, MD, USA
  • University of Southern California (US)
Corresponding author
Klonoff, David C.
Venue
Journal of Diabetes Science and Technology
Published
2022-07-20
Volume
17
Issue
6
Pages
1686-1697
ISSN
1932-2968 (ISSN-L)
OpenAlex
W4286210600
Cited by
93
References
70
Citations by year
2026: 26 · 2025: 40 · 2024: 14 · 2023: 12 · 2022: 1
FWCI
12.41
Type
journal article
Language
en
Open access
Locations
  • Journal of Diabetes Science and Technology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (UL1TR001855)
  • U.S. Food and Drug Administration (P50FD006425)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Physiology › Physical Activity and Health
Keywords
continuous glucose monitoring, non-diabetic population, athletic performance, diabetes prevention
MeSH terms
Blood Glucose, Diabetes Mellitus, Type 1, Humans, Insulin, Blood Glucose Self-Monitoring, Insulin, Regular, Human

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review